Individualized Functional Connectivity Targeting in aiTBS for Depression
| Заболевание | Depressive Disorder, Major, Depression, Mood Disorders, Mental Disorder |
|---|---|
| Фаза | Фаза 2 |
| Спонсор | Brigham and Women's Hospital |
| Статус | Завершено |
| Участники | 40 участн. |
| Вмешательство | transcranial magnetic stimulation |
| Дата начала | 15.07.2023 |
| Дата завершения | 17.03.2025 |
| Публикация результатов | 7.07.2026 |
Кратко
The goal of this clinical trial is to estimate the importance of neuroimaging in accelerated intermittent theta burst stimulation (aiTBS) for depression. Participants will receive aiTBS treatment, but they will not know if their treatment spot was found with neuroimaging or head measurements.
Montgomery-Åsberg Depression Rating Scale (MADRS)
| Connectivity-based Targeting | 35 Scores on scale |
|---|---|
| Scalp-based Targeting | 31 Scores on scale |
| Connectivity-based Targeting | 6 Scores on scale |
| Scalp-based Targeting | 11 Scores on scale |
Открыть в BENITIONS Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
- CBT+ for Depression — University of Wisconsin, Madison
- Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
- Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
- Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for — Levomecor Inc.
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders — Massachusetts General Hospital